The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Pharmacodynamic Assays, 2013Measuring LRRK2 Phosphorylation by Flow Cytometry
Objective/Rationale:
There is a possibility that inhibitors of the leucine-rich repeat kinase 2 (LRRK2) protein could be used for treating Parkinson’s disease. Our projects aims to develop... -
LRRK2 Cohort Consortium Resource Request, 2013Penetrance of LRRK2 in the LRRK2 Cohort Consortium
Objective/Rationale:
Estimates for development of Parkinson’s disease (PD) and age of onset in carriers of LRRK2 G2019S mutations vary widely (24 to 100% by age 80). Factors including... -
LRRK2 Pharmacodynamic Assays, 2013Development of a Sensitive Assay to Correlate LRRK2 Kinase Activity and Conformational State
Objective/Rationale:
A major function of LRRK2, a protein kinase, is the modification of other proteins through a process known as phosphorylation. It appears that the kinase activity of... -
Synuclein Therapeutic Acceleration Program, 2013Pre-clinical Development of a Vaccine Against Alpha-synuclein Based on Virus-like Particles
Objective/Rationale:
Overexpression of the protein alpha-synuclein has been identified as a major cause for the development of Parkinson’s disease (PD) in humans. Lewy bodies, which... -
Synuclein Therapeutic Acceleration Program, 2013Development of the Alpha-Synuclein Stabilizer NPT200-11 for the Treatment of Parkinson’s Disease
Objective/Rationale:
A role for the synaptic protein alpha-synuclein in Parkinson’s disease is suggested by human genetic studies, the histopathology in patients with Parkinson’s disease and studies... -
Rapid Response Innovation Awards, 2013Alpha-Synuclein Effects on Fusion Pore Expansion and Protein Secretion
Objective/Rationale:
Alpha-synuclein, implicated in Parkinson’s disease, is normally expressed in nerve terminals, from which neurotransmitters are released by fusion of their granule membrane with the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.